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a b s t r a c t
Several studies demonstrate that inflammation affects body odor. Volatile signals associated with inflammation induced by pyrogens like LPS are detectable both by conspecifics and chemical analyses. However,
little is known about the mechanisms which translate detection of a foreign molecule or pathogen into a
unique body odor, or even how unique that odor may be. Here, we utilized C57BL/6J trained mice to identify the odor of LPS-treated conspecifics to investigate potential pathways between LPS-induced inflammation and changes in body odor, as represented by changes in urine odor. We hypothesized that the
change in volatile metabolites could be caused directly by the pro-inflammatory cytokine response mediated by TNF or IL-1b, or by the compensatory anti-inflammatory response mediated by IL-10. We found
that trained biosensors generalized learned LPS-associated odors to TNF-induced odors, but not to IL-1b
or IL-10-induced odors. Analyses of urine volatiles using headspace gas chromatography revealed distinct
profiles of volatile compounds for each treatment. Instrumental discrimination relied on a mixture of
compounds, including 2-sec-butyl-4,5-dihydrothiazole, cedrol, nonanal, benzaldehyde, acetic acid, 2ethyl-1-hexanol, and dehydro-exo-brevicomin. Although interpretation of LDA modeling differed from
behavioral testing, it does suggest that treatment with TNF, IL-1b, and LPS can be distinguished by their
resultant volatile profiles. These findings indicate there is information found in body odors on the presence of specific cytokines. This result is encouraging for the future of disease diagnosis via analysis of
volatiles.
Ó 2017 Elsevier Inc. All rights reserved.

1. Introduction
Body odors often contain information about the physiological
state of the producer. In many species, including mice, body odor
contains information on age, sex, genetics, diet, reproductive status, dominance, and health (Kimball et al., 2014, 2016a; Kwak
et al., 2008, 2010; Novotny, 2003; Olsson et al., 2014; Osada
et al., 2008; Penn and Potts, 1998). The ability to detect illness or
infection in conspecifics has obvious potential advantages. Evidence indicates odor cues allow this detection in multiple species,
especially rodents (Arakawa et al., 2011; Boillat et al., 2015; Penn
and Potts, 1998). For example, female mice demonstrate reduced
attraction to the odors of male conspecifics infected with parasites
or a respiratory virus (Kavaliers and Colwell, 1995; Kavaliers et al.,
1998; Penn et al., 1998). Treatment of rats with lipopolysaccharide
(LPS) or IL-1b results in avoidance by healthy conspecifics
(Arakawa et al., 2011). However, pretreatment with the antiinflammatory cytokine IL-10 blocked production of the aversive
⇑ Corresponding author.
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odor (Arakawa et al., 2010). These findings suggest that cytokines
serve as mediators of disease-induced odors. It is unclear, however,
which cytokines specifically contribute to disease-related odors
and how they impact the volatile metabolome as a whole.
Cytokine responses to inflammatory stimuli such as pathogens
often represent a complex series of events. When faced with a
common pathogen associated molecular pattern (PAMP) like LPS,
there is rapid production of pro-inflammatory cytokines, most
notably TNF and IL-1b (Bradley, 2008; Zuckerman et al., 1991).
LPS rapidly induces TNF, which induces its own production in
macrophages (Vassalli, 1992). TNF also induces production of IL1b in leukocytes (Dinarello et al., 1986), which must be processed
by an activated inflammasome before it can be secreted (Burm
et al., 2015). Both cytokines activate the vascular epithelium,
induce the febrile response, and aid in the recruitment of effector
immune cells. TNF also activates the respiratory burst in phagocytes and increases vascular permeability (Bradley, 2008). Following shortly after the inflammatory response is a compensatory
anti-inflammatory response, primarily regulated by the cytokine
IL-10 (Bone, 1996; Moore et al., 2001). IL-10 inhibits production
of IL-1b, TNF, IL-6, and numerous other inflammatory cytokines
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(Fiorentino et al., 1991; Moore et al., 2001; Opal and DePalo, 2000;
Malefyt et al., 1991). This limits the damage done by inflammatory
mediators, promotes tissue repair, and promotes restoration of
homeostasis (Ariel and Timor, 2013).
Given the wide ranging effects of cytokine signals to immune
and metabolic tissue (Chen et al., 2009; Doerrler et al., 1994;
Grimble, 1996; Hardardottir et al., 1992; Moldawer et al., 1988;
Oberholzer et al., 2002), we hypothesized that cytokine signaling
mediates changes in body odor occurring in response to treatment
with LPS. To test this, we first demonstrated LPS induced a robust
inflammatory and anti-inflammatory response, as reported many
previous studies (Bone, 1996; DeForge and Remick, 1991;
Mezayen et al., 2007; Fiorentino et al., 1991; Lu et al., 2008,
Tateda et al., 1996). Next, we tested the hypothesis that proinflammatory cytokines TNF and IL-1b would each elicit changes
in body odor (determined behaviorally) and changes in the volatile
metabolome (determined chemometrically) similar to those
induced by treatment with LPS. We used urine as our source of
body odor for several reasons, most importantly the central role
of urine odors in regulating mouse behavior and physiology
(Beauchamp and Yamazaki, 2003). Urine also serves as a useful
source of body odors due to its relative ease of collection, ability
to be collected from the same animal multiple times without
harming the animal, and the fact urine odor contains most of the
volatile chemicals found in mouse body scent (Rock et al., 2006).
We also tested the alternate hypothesis that IL-10 produces a similar urine odor to LPS. Although IL-10 has an opposing inflammatory effect, we hypothesized its downstream effect may be
responsible for urine odor alteration. To test these hypotheses,
we used odor trained biosensor mice, as well as GC/MS headspace
chemical analysis. Both of these techniques have been successfully
employed to study persistent changes in volatile profiles occurring
as a consequence of disease, inflammation, and injury (Kimball
et al., 2014, ;Kimball et al., 2016b,a; Hanai et al., 2012; Singer
et al., 1997; Yamazaki et al., 2002) but they seldom have been used
in tandem. In doing so, we tested a third hypothesis that these two
techniques would provide consistent and complimentary
outcomes.
2. Methods
2.1. Subjects
Inbred male C57BL/6 mice were commercially purchased (Jackson Laboratories, Bar Harbor, ME) for use as urine, blood, and tissue
donors as well as trained biosensors. Mice received LPS or cytokine
treatments at 6–8 weeks of age, consistent with previous studies
(Kimball et al., 2014). This study did not investigate the effects of
age on inflammation-induced urine odor. Donor mice were provided ad libitum access to food (Teklad Rodent Diet) and water.
Biosensor mice were give ad libitum access to food but underwent
water restriction for 23 h prior to Y-maze experiments. Biosensors
received water during and after experiments. Health and bodyweight of biosensors was monitored daily during water restriction.
Mice were taken out of the training panel and given access to water
if their body weight ever dropped 10% below the previous reading,
or if biosensors showed any signs of illness. All procedures involving animals were approved by the Monell Institutional Animal Care
and Use Committee, protocols #1123 and #1174.
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ous experiments have demonstrated this dosage is sufficient to
generate a change in subject urine odor (Kimball et al., 2014).
We note that our dose of LPS was much milder than other values
used in related studies that have been as high as 12 mg/kg
(Vuaden et al., 2011). Mice treated with cytokines received 100
lL i.p. injections of 30 lg/mL TNF, IL-1b, or IL-10 (BioLegend, San
Diego, CA) in sterile PBS (Cook et al., 2006). These cytokine doses
triggered cascades with final concentrations close to those seen
in serum following LPS injections (Figs. 1 and 2).
2.3. Urine collection
Urine was collected nearly daily from treated donors by application of gentle abdominal pressure as described previously
(Yamazaki et al., 1983). Urine volumes collected were typically
10–50 lL per mouse per day, although efforts to collect from individual mice frequently resulted in no volume collected. Collection
continued for 30 days. Vials of urine were stored at 20 °C for later
behavioral and chemical analyses.
2.4. Blood collection
Blood was collected in one of two ways. Mice were anesthetized
with 2% isoflurane using a small-animal inhalation anesthesia
apparatus. While unconscious, 100 lL blood was collected from
the tail vein. Blood was only collected once per mouse in this fashion. Alternatively, as a terminal procedure, up to 1.5 mL blood was
collected from anesthetized mice via cardiac puncture. Isoflurane
was then increased to euthanize animal. Blood was immediately
processed as described below.
2.5. RNA extraction
After isolation from the mouse, blood was centrifuged in 1.5 mL
tubes at 2500g for 7.5 min to pellet red blood cells. Serum was
removed and stored at 40 °C. Remaining cells underwent hypertonic lysis for 20 s before normal saline levels were restored. Samples were then rinsed with PBS and remaining cells were lysed
with TRIzol reagent (Thermo Fisher Scientific, Wilmington, DE).
RNA extraction proceeded as per manufacturer’s instructions.
Briefly, cell pellets were lysed in TRIzol and extracted with chloroform. The aqueous phase was combined with isopropanol to precipitate RNA. RNA samples were purified through additional
precipitation with 5 M ammonium acetate and ethanol. Purity of
samples was verified using a Nanodrop 1000 (Thermo Fisher Scientific, Wilmington, DE).
2.6. Quantitative PCR
After RNA purification, RNA was reverse transcribed using HighCapacity cDNA Reverse Transcription kits (Applied Biosystems,
Foster City, CA). Resulting cDNA was then quantified using the Fast
SYBR Green system using the StepOne Real-Time PCR System. Bactin was also run as a loading control. The following primers were
used:
TNF,
Forward-TGGCCTCCCTCTCATCAG,
ReverseACTTGGTGGTTTGCTACGAC; IL-1b, Forward-CCCAACTGGTACAT
CAGCACCTC, Reverse-GACACGGATTCCATGGTGAAGTC; IL-10, For
ward-GCCCTTTGCTATGGTGTCCTTTC, Reverse-TCCCTGGTTTCTCTT
CCCAAGAC;
B-actin,
ForwardTGTTACCAACTGGGACGACA,
Reverse- CTGGGTCATCTTTTCACGGT.

2.2. Treatments
2.7. ELISA
Donors used to generate urine for Y-maze training were treated
with 300 lL i.p. injections of either 0.01 M sterile phosphatebuffered saline (PBS) or 0.2 mg/mL, yielding an approximate dose
of 2 mg/kg LPS in sterile PBS (Sigma-Aldrich, St Louis, MO). Previ-

ELISA assays of serum for TNF, IL-1b, and IL-10 were performed
using DuoSet ELISA kits, according to manufacturer’s instructions
(R&D Systems, Minneapolis, MN).
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2.8. Behavioral assay
A Y-maze apparatus was used for odor training and generalization assays as previously described (Kimball et al., 2016a;
Yamazaki et al., 2002). Six biosensor mice were first trained to identify the odor associated with LPS by providing the choice of urine
odor derived from an LPS-treated donor and urine odor derived from
a PBS-treated donor. To generate these odors, urine samples (0.25
mL) were placed in petri dishes and loaded into separate odor chambers. Urine samples collected from individual mice over multiple
days were pooled by donor for this purpose. Pooled urine included
samples collected from days 4 to 25 after treatment. Previous
unpublished work in our laboratory indicated that persistent urine
odor differences are still present 4 weeks after treatment. Each
pooled urine sample was used for a single day of testing and then
discarded. Air was blown over the samples and into either arm of
the Y-maze. A biosensor mouse was place in the central arm of
the Y-maze and allowed to choose between the two arms containing
the two odors. Gates were manually lowered and raised to permit
training or testing of biosensor mouse. During training, mice choosing the arm of the Y-maze containing LPS odor were rewarded with
a drop of water. Samples were randomly assigned to left or right
arms of the Y-maze for each trial of a session. During training, sessions consisted of approximately 35 water-rewarded trials. Biosensor training and experimentation took place in 3 stages.
2.8.1. Training
Rewarded training trials are employed to teach biosensors to
discriminate the urinary volatiles resulting from treatment with
LPS and PBS. The reward is associated with LPS odor to promote
generalization of this response in later sessions. To reduce the possibility that biosensors were learning individual identities of
donors rather than the donor’s treatment (i.e. PBS, LPS), each training set consisting of urine from three different donors (for each
treatment). Dishes were offered singly or in combinations of two
to three (keeping treatment consistent), resulting in 19 unique
pairs of odor stimuli. This procedure sought to acclimatize the
biosensors to not receiving a reward on every trial, even if they
behaved ‘‘correctly”.
2.8.2. Extinctions
Extinction trials are introduced so that biosensors become
acquainted with unrewarded trials. Such intermittent reinforcement also serves to strengthen the operant response (Bodyak and
Slotnick, 1999). Once biosensors chose the LPS-treated mouse
urine odor 75% of the time (in 2 consecutive sets of 12 trial
blocks), extinction trials were implemented. These trials consisted
of unrewarded trials interspersed among rewarded trials of LPS
and PBS urines. The training samples were used as stimuli during
extinctions.
2.8.3. Generalizations
Unrewarded generalization trials are used to test the biosensors. Because LPS odor was associated with the reward in training,
these trials can be used to determine which test stimuli are most
similar to LPS. Once biosensors demonstrated they could maintain
their identification rate when faced with unrewarded trials,
biosensors faced generalizations, wherein novel samples were
used as stimuli. The first generalization set was to novel donors
receiving either LPS or PBS. Urine collected from a subset of animals in the training cohort was set aside and not used in any initial
training trials. Novel donor generalizations were the first time
biosensor animals were exposed urine collected from that individual animal. After generalization, any remaining urine from that
individual was used as training urine. Generalizations to donors
treated with novel test stimuli (i.e. cytokines) were only initiated

after biosensors demonstrated their ability to correctly identify
novel LPS-treated donors. These novel treatment generalizations
were run multiple days apart. Generalization trials were run on a
minimum of 3 separate days per treatment, each day alternating
between different treatments.
2.9. GC/MS headspace
Twenty five microliter urine samples fortified with 100 ng of Lcarvone by addition of 10 lL aqueous solution of as an internal reference were analyzed using a HT3 dynamic headspace analyzer
(Teledyne Tekmar, Mason, OH) outfitted with Supelco Trap K
Vocarb 3000 thermal desorb trap (Sigma-Aldrich, St Louis, MO),
attached to a Thermo Scientific ISQ GC-MS equipped with a single
quadrupole mass spectrometer (Restek, Bellefonte, PA), as
described elsewhere (Kimball et al., 2016a,b). Urine samples were
maintained at 40 °C and swept with helium for 10 min at a flow
rate of 75 mL/min. Volatiles were collected directly on the thermal
desorption trap. The trap was desorbed at 260 °C directly into gas
chromatograph. Split injections (5:1) were made using a 2.0 mL/
min column flow and 10.0 mL/min split vent flow. The GC oven
began at 40 °C for 3 min, increased temperature at a rate of 7 °C/
min until reaching 260 °C. The mass spectrometer was operated
in scan mode from 33 to 400 m/z. Peak identifications were
assigned based on the spectral library search of the NIST Standard
Reference Database. Vials containing 100 ng of L-carvone without
urine and entirely empty vials were periodically analyzed as well.
2.10. Behavioral data analysis
Generalization data from the six biosensors were pooled across
sessions into total number correct and total number of trials. Data
were then subject to two-tailed binomial proportion hypothesis
testing using the PROC FREQ function of SAS Studio. Each pool of
data contained 75 trials. Significance was determined by exact
test of binomial proportion.
2.11. Chemometric data analysis
Chromatographic data were exported for baseline correction,
noise elimination and peak alignment by Metalign software
(Lommen, 2009). MSClust was then used on resulting multivariate
data files for mass spectral extraction (Tikunov et al., 2012). Individual peak responses were standardized to the L-carvone response
in that particular sample. Sample outliers were identified using
influence plots in Unscrambler (CAMO Software) to identify samples with abnormally high residual variance and leverage. Subject
means of all carvone-standardized peak responses were calculated
for individual mice. Sample means consisted of 3–5 samples, which
for LPS and PBS samples were collected from days 4 to 16, during
which time trained biosensors can detect a difference in odor
(Kimball et al., 2014). Samples from days 1 to 8 from cytokinetreated animals were used for chemometric analysis. Donors were
then assigned to specific data sets for model building and prediction using linear discriminant analysis (LDA). Data set 1 consisted
of donors receiving LPS and PBS treatments generated for Y-maze
training. To bolster samples size, data set 1 also included samples
from mice that were restricted from food for 48 h immediately following injections (LPS-injected mice normally fast for 48 h even
with ad libitum access). Data set 2 consisted of donors receiving
IL-10, IL-1b, TNF, and PBS treatments generated for Y-maze generalizations. Data set 3 consisted of a second cohort of LPS treatments generated for Y-maze training.
LDA models were first constructed with donor means from data
set 1 using PROC STEPDISC in SAS to identify those chromatographic peaks which contribute to discrimination of the LPS-

P. Millet et al. / Brain, Behavior, and Immunity 69 (2018) 312–320

treated mouse urine vs. PBS-treated mouse urine. Contingency
tables for LPS and PBS classifications resulting from the model
were constructed using PROC DISCRIM and cross-validation was
employed to evaluate LDA results. Individual samples from data
sets 2 and 3 were then subjected to LDA classification (PROC DISCRIM in SAS) using the previously generated LDA model for LPS
vs. PBS. The significance of these LDA classifications was then
determined through an exact test of binomial proportion with a
null hypothesis of 0.5.
These analyses were then repeated, except that in this instance
model building was conducted with donor means from data set 2
to identify those chromatographic peaks which contributed to discrimination among IL-10, IL-1b, TNF, and PBS treatments. Individual samples from data sets 1 and 3 were then subjected to LDA
classification using this model generated from data set 2. The significance of these LDA classifications was then determined through
an exact test of binomial proportion with a null hypothesis of 0.25.
Pairwise comparisons were made between treatment groups
using one-way ANOVA assays for those peaks contributing to the
LDA models. One-way ANOVA analysis was performed using individual means for each mouse, correcting for the false discovery rate
using multiple tests (Benjamini and Hochberg, 1995).

3. Results
3.1. LPS induces cytokine response
As anticipated, mice treated with LPS exhibited numerous signs
of illness for the first 24–48 h. Symptoms included lethargy,
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reduced food intake, and weight loss. We analyzed cytokine mRNA
expression in peripheral blood leukocytes (PBLs) (Fig. 1A–C). We
saw significant increases in TNF, IL-1b, and IL-10 mRNA in LPS vs.
saline treated animals. These increases were present 24 h following injection, but returned to baseline by day 5. No significant
increases in IL-4, IL-6, or IFN-g were observed (data not shown).
Additionally, we observed significant levels of TNF, IL-1b, and IL10 protein in the serum during the first 24 h (Fig. 1D–F). IL-1b
and IL-10 levels were relatively consistent during that period. Circulating levels of TNF quickly dropped, consistent with prior
reports of the cytokine’s short half-life in vivo (Beutler et al.,
1985; Flick and Gifford, 1986).
After verifying the TNF, IL-1b and IL-10 cytokine responses in
our model, our next step was to treat mice with these individual
cytokines. Levels of circulating cytokines were measured at 4 h
and 24 h following treatment (Fig. 2).

3.2. Biosensors generalize to specific pro-inflammatory cytokines
Trained biosensors identified LPS urine at a rate of 93% during
rewarded training trials (Fig. 3). This rate fell to 75% when asked
to identify novel conspecific odors with the same treatment. This
type of decline in recognition is typically observed in Y-maze trials
when biosensors are faced with odors from novel conspecifics,
even ones that are presumably genetically identical to the training
mouse urines (Kimball et al., 2014). Despite our best efforts, it is
possible that biosensors incorporate some information on the individual identities of the donor animals into their discrimination task
learning during rewarded trials. Testing with novel donors receiv-

Fig. 1. A–C) qPCR analysis of isolated PBLs following i.p. injections of saline, 0.2 mg/kg LPS. Columns represent fold change in A) TNF; B) IL-1b; C) IL-10 mRNA, relative to Day
1 Saline sample. D–F) ELISA analysis of serum concentrations of D) TNF, E) IL-1b, and F) IL-10 protein levels following i.p. injections. Bars represent SEM (n = 3).
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ing the same treatments used for training permits is used to
demonstrate that biosensors are making discriminations on the
basis of treatment, not individual donor identity. Accordingly, this
identification rate was significantly greater than 50% identification
expected by chance (75%; p = .006) demonstrating that the trained
mice differentiated LPS-induced odor, not individual donors.
As we hypothesized, biosensors generalized their training to
TNF-induced odor (71%; p = .0003). However, this training did
not generalize to IL-1b vs. PBS-induced odor (57%; p = .2461). This
indicated the biosensors perceived a similarity between LPS and
TNF-induced odor, but not IL-1b-induced odor. This distinction
was not predicted by our hypothesis.
3.3. Biosensors do not generalize to anti-inflammatory cytokine
Biosensors trained to LPS-induced urine odor were also asked to
generalize their training to IL-10 induced urine odor (Fig. 3). Here,
biosensors generalized to the cytokine signal only 38% of the time.
Lack of generalization to IL-10 induced odor, as evidenced by selection of control odor at a rate significantly greater than chance (62%;
p = .05), indicated the biosensors did not perceive a similarity
between IL and 10 and LPS-induced odor. It further suggests IL10 induces its own distinctive odor which biosensors perceived
as different from training odors.
3.4. Chemometric discriminations differ from those from biosensors

Fig. 2. ELISA analysis of serum samples following i.p. injections of TNF, IL-1b, IL-10,
saline, or 0.2 mg/kg LPS. Columns represent ng/lL in A) TNF; B) IL-1b; C) IL-10
cytokine at 4 and 24 h after injection. Bars represent SEM (n = 3).

Urine samples from the behavioral experiments underwent
headspace GC/MS analyses. We used donors from data set 1 (LPS
and PBS treatments) to construct an LDA model that best separated
the treatments while minimizing the number of chemical predictors. The model consisted of five chemical predictors (nonanal,
benzaldehyde, dehydro-exo-brevicomin (DHB), acetic acid, and 2ethyl-1-hexanol). The overall cross-validation error rate was
11.1%, meaning that error was low even when individual samples
were held out of model building and rerun. We then used this
model to make predictions for a different cohort of mice receiving
LPS (data set 3) and for donors receiving cytokine treatments (data
set 2). No data from analyses of these mice were used in model
building. The majority (17 of 24) of samples from donors in data
set 3 (LPS-treated) were classified as LPS with our discriminant
model based solely on data set 1. All of the samples from IL to
1b-treated donors (15 of 15) were categorized as LPS by this model
(Table 1), however samples from TNF- and IL-10-treated donors

Fig. 3. Mean responses of trained biosensors. Bars represent 95% confidence intervals. Training trials (shaded) were rewarded, while generalization trials (white) were
unrewarded. Labels indicate (*) p < .05, (**) p < .01 or (***) p < .001 for a two-tailed exact binomial test of the hypothesis that identification differs from 50%.
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Table 1
Cross-categorization of TNF, IL-1b, IL-10 and LPS samples into the LPS vs PBS LDA
model. LPS samples categorized here represent a different data set (data set 3) not
used to build the model. *: p < .05, ***: p < .001 by exact test of binomial proportion.
Cross-Categorization

LPS*
IL10
IL-1b***
TNF

LPS

PBS

70.8%
(17 of 24)
53.3%
(8 of 15)
100%
(15 of 15)
51.6%
(16 of 31)

29.2%
(7 of 24)
46.7%
(7 of 15)
0%
(0 of 15)
48.4%
(15 of 31)

were evenly split between LPS and PBS categorizations. In contrast
to the behavioral assay, the chemometric model suggested LPSinduced volatiles were more similar to IL-1b- than TNF-induced
volatiles.
We next constructed a model to discriminate among IL-10, IL1b, TNF, and PBS using data set 2. Three predictors (2-sec-butyl4,5-dihydrothiazole (SBT), acetic acid, and cedrol) yielded a model
with an overall cross-validation error rate of 24.4%. When this
model was used to classify LPS donors from data sets 1 and 3,
52.9% of LPS donors were classified as TNF (Table 2). The remaining
LPS samples were evenly distributed among the other 3 categories:
IL-1b (11.8%), IL-10 (17.7%) and PBS (17.7%). Finally, we conducted
pairwise analysis on all metabolites identified by our models
(Table 3). Only one metabolite, SBT, showed a significant pairwise
reduction in response to a specific treatment, which in this case
was IL-1b.
4. Discussion
In this study, we sought to explore the immune signaling events
involved in the generation of LPS-mediated urine odor change. Previous work found that treatment with either LPS or IL-1b induced
an acute odor aversive to conspecifics during the first 4 h after
intracerebroventricular (icv) infusion (Arakawa et al., 2010). This
study follows the novel discovery that urine odor alteration due
to treatment with LPS or head injury persists for many weeks
(Kimball et al., 2014, 2016a). This surprising effect occurs even
though the acute physiological effects of inflammation (cytokine

Table 2
Cross-categorization of LPS samples into the TNF, IL-1b, IL-10 vs PBS LDA model. ***:
p < .001 by exact test of binomial proportion.
Cross-Categorization

LPS

TNF***

IL1B

IL10

PBS

44.2%
(23 of 52)

9.6%
(5 of 52)

26.9%
(14 of 52)

19.2%
(10 of 52)

Table 3
Pairwise comparisons of significance for all metabolites contributing to either
discriminant model. **: p < .01.
Metabolite

Pairwise

2-sec-butyl-4,5-dihydrothiazole (SBT)
Cedrol
Nonanal
Benzaldehyde
Acetic Acid
2-Ethyl-1-hexanol
Dehydro-exo-brevicomin (DHB)

IL-1b lower**
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expression in particular) subside within hours or days of the
inflammatory event. It is entirely plausible that there are acute
changes in body odor during the early hours of inflammation when
cytokines are still circulating that our study would not detect.
However, the work presented here focusses primarily on urine
odor signatures several days to weeks following LPS administration
during which time the odor signal remains stable based on previous work. We consider not only the involvement of proinflammatory cytokines TNF and IL-1b on this persistent odor
change, but the compensatory anti-inflammatory response mediated by IL-10.
To study the role of these cytokines in persistent urine odor
changes, we began by confirming these cytokine responses were
present in our experimental system. We then proceeded to treat
mice with these individual cytokines. While the cytokine appeared
to clear from the serum more quickly when injected individually
rather than induced through LPS administration, we were able to
confirm similar levels of cytokines were present in both LPS and
individual cytokine treatment systems.
Our first behavioral experiment tested whether mice trained to
enter the arm of the Y-maze scented by LPS-induced odor would
generalize this learned response to TNF and IL-1b. We hypothesized that biosensors would generalize their training with LPS to
both inflammatory cytokines. Surprisingly, biosensors generalized
to TNF-induced odor, but not IL-1b-induced odor, confirming only
one part of our first hypothesis. We also tested the alternate
hypothesis that LPS-induced urine odor resulted from the compensatory anti-inflammatory response, rather than the inflammatory
response itself by determining whether LPS-trained biosensors
generalized to IL-10-induced urine odor. We rejected this second
hypothesis, as LPS-odor trained biosensor mice did not generalize
to the IL-10-induced odor.
In parallel, we used GC/MS headspace to analyze the volatile
metabolites present in the urine. Mirroring our training and generalization approach of the Y-maze, we first constructed a LDA model
to discriminate between LPS and PBS treatments. Then, based on
the generalization pattern of the Y-maze experiments, we made
predictions with donors receiving specific cytokine treatments.
We hypothesized that doing so would yield results consistent with
our behavioral data. However, our chemometric model did not
yield the same discrimination that the biosensors did. We next
reversed the data sets used for model building and prediction. This
enabled us to perform an experiment that would not be possible in
the Y-maze, namely, to ‘‘train” the model on the volatiles produced
by treatment with several different cytokines and then make predictions based on the compounds identified in the model for the
discrimination between LPS and PBS donors. This approach categorized the LPS samples as most similar to TNF, which is consistent
with our behavioral data.
Biosensor mice were trained to differentiate between urine
odors from saline and LPS-treated conspecifics collected no earlier
than four days post-treatment. This is well after the cytokine
response has peaked and the plasma has been largely cleared of
detectable levels of circulating inflammatory and antiinflammatory cytokines (Fig. 1). This effect does not appear to be
dependent on IL-10. While IL-10 is produced in response to TNF
and IL-1b and is generally found later in the course of acute inflammation (Moore et al., 2001; Opal and DePalo, 2000), our data indicate that it does not produce an odor profile to which LPS-trained
biosensor mice generalize. Inflammation-induced changes in odor
and the volatile metabolome is therefore a downstream effect of
inflammation and cytokine signaling. Our data suggest that TNF
is the upstream mediator of LPS-induced changes in odor.
Our finding that TNF- and IL-1b-induced odors do not elicit the
same generalization responses from the biosensors was particularly surprising since TNF and IL-1b generally have very similar
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cellular effects in immune tissue. Both trigger degradation of IkBa,
translocation of NF-kB to the nucleus, and activation of inflammation (Medzhitov et al., 1998; Zhang et al., 2011). The physiological
effects of TNF and IL-1b are also very similar. Both induce fever,
stimulate expression of C-reactive protein, and upregulate expression of adhesion molecules (Dinarello et al., 1986; Gabay and
Kushner, 1999; Oberholzer et al., 2000). Their effects, however,
are not identical. One possible explanation for the biosensors generalization to TNF but not IL-1b is sequence of the inflammatory
cytokine cascade. TNF is the primary stimulator of IL-1b
(Dinarello et al., 1986; Feldmann et al., 1996). IL-1b, however,
induces IL-6, which downregulates TNF (Aderka et al., 1989;
Dinarello, 2009). While IL-1b has some capacity to induce TNF,
TNF signaling is generally upstream of IL-1b expression.
Our behavioral data suggest that one or more of the downstream effects of TNF not mediated by IL-1b may be responsible
for LPS-induced urine odor. What specific effect or effects are
involved is still unclear. Aside from its role in activating fever
and inflammation, a role it shares with IL-1b, TNF has several functions all its own. TNF blocks fatty acid synthesis, increases
glycogenolysis, lipolysis, and lactate production (Lee et al., 1987;
Moldawer et al., 1988). Rats injected with TNF show increased hepatic citrate levels, leading to more free fatty acid synthesis in the
liver and higher free fatty acids in serum (Chen et al., 2009;
Grunfeld et al., 1988). Within 2 h, TNF administration to NMRI
mice causes hypoglycemia and around 80% loss of liver glycogen
(Mahony and Tisdale, 1990). The mechanism by which TNF mediates these effects is unclear. While it is possible that some metabolic effects of TNF are in actuality the result of another
downstream cytokine like IL-1b, the two inflammatory mediators
seem to have different metabolic effects in adipocytes (Doerrler
et al., 1994). In 3T3-F442A adipocytes, TNF, IFN-a, and IFN-c each
decrease levels of acetyl-CoA carboxylase (ACC), while IL-1b
slightly increased expression of ACC. Both cytokines are capable
of blocking lipoprotein lipase (LPL) in adipocytes, but only TNF
can promote the production of prostaglandin E2, a potent inhibitor
of lipolysis (Hardardottir et al., 1992).
The third hypothesis tested in this study was that results from
behavioral tests and from the chemometric analyses would produce similar or consistent results. Underlying this hypothesis is
the hope that the volatile compound changes that allow animals
to identify a diseased animal’s odors overlap with those that are
identified in chemical analyses. However, there are good reasons
to be skeptical that this is the case and the results from this study
are equivocal. While the behavioral assays indicated that TNFinduced odor was similar to LPS-induced odor, the first set of
chemometric assays (Table 1) suggested that cytokine-induced
changes in volatiles are difficult to separate from one another.
The initial data suggest while the pattern of TNF-induced volatiles
resembled those of LPS-treated animals, the pattern of IL-1binduced volatiles was more alike. When a different chemometric
approach was used (Table 2), it provided evidence that LPS volatiles shared more with TNF volatiles than with PBS, IL10 or IL-1b
volatile patterns, as we predicted from the behavioral results. We
might therefore infer that the metabolites identified in our second
model are more likely to be involved in the biosensor perception of
inflammation-induced body odor.
Many of the metabolites identified by our LDA modeling have
been observed in previous studies of murine volatiles and pheromones. Two murine pheromones, SBT and DHB were identified in
our modeling. Both pheromones have previously been demonstrated to increase male aggression and to be drastically reduced
in castrated mice (Novotny et al., 1985; Schwende et al., 1984).
Previous work has demonstrated SBT decreases in response to
stress (Schaefer et al., 2010), a response which seems to occur during inflammation as well. Benzaldehyde levels are also known to

change with stress and with genetic background (Kwak et al.,
2008). Cedrol, a sesquiterpine compound found in cedar, is
undoubtedly a byproduct of the red cedar bedding used in our
housing. We speculate that the decrease in cedrol observed in animals treated with an inflammatory agent reflects a decline in the
amount of bedding animals consumed, or possibly a change in
mouse metabolism following injection.
Whether the microbiome is responsible for any of the changes
in urine odor and volatile metabolites is unknown. The cometabolome arising from metabolic interactions of the host and
its microbiome is known to cause alterations in the metabolite signature of host fluids such as urine (Nicholson et al., 2005). Furthermore, the gut microbiome is directly altered by certain
inflammatory irregularities or conditions with chronic inflammation (Slack et al., 2009; Faber and Baumler, 2014). Thus, inflammatory events may alter the volatile metabolome via a similar
interaction. For example, TLR5 deficient mice show altered gut
microbiota, as well as the hallmark symptoms of metabolic syndrome (Vijay-Kumar et al., 2010). The metabolic syndrome phenotype appears to arise directly from the alteration of gut microbiota.
For example, when germ-free wild-type mice receive a transfer of
gut microbiota from the TLR5 deficient mouse, the metabolic syndrome phenotype is transferred as well. Chronic conditions which
cause inflammation, such as chronic kidney disease and nonalcoholic fatty liver disease, can alter the products of intestinal
flora, as measured by volatile organic compounds in fecal samples
(Meinardi et al., 2013; Reid et al., 2016). Inflammation associated
with inflammatory bowel disease (IBD) is also known to impact
the gut microbiome and the volatile metabolites from fecal samples (Arasaradnam et al., 2009). While these findings implicate
the microbiome as a contributor to alterations of the volatile metabolome, we are not aware of any studies that demonstrate acute
inflammation affects the gut microbiome and the associated volatile metabolome. Determining if, or how, acute inflammation
affects the microbiome could potentially be a rich area of research.
On the surface, our results appear to contradict the findings of the
Arakawa group that demonstrate IL-1b treatment in rats induced
an odor that was aversive to conspecifics (Arakawa et al., 2010).
Our data indicate that IL-1b treatment generates an odor which
biosensors do not perceive as similar to LPS-induced odor. The reason for these differences likely stems from the differences in
methodology between that study and our own. Previous research
by Boillat et al. (2015) demonstrated the essential role played by
the vomeronasal organ (VNO) in sick conspecific avoidance. Considerable evidence suggests the VNO responds primarily to nonor low-volatile compounds (Brennan and Kendrick, 2006). Much
of the work demonstrating conspecific avoidance has used models
where the involvement of low- and non-volatile compounds was
more plausible (Arakawa et al., 2010; Boillat et al., 2015; Zala
et al., 2015). The design of the Y-maze ensures that biosensor mice
come nowhere near the sample itself, implying that their decision
is based entirely or at least primarily on volatile compounds which
are most likely detected by the main olfactory system, not the
VNO. Interestingly, we informally observed that in the context of
the Y-maze, biosensor animals have no particular aversion to the
odors of LPS-treated conspecifics, even during early stages of
training.
Behavioral studies can demonstrate that an odor differences
exists. For those interested in the diagnostic value of odor, we
argue that this is a logical first step. The olfactory system is the
most sophisticated detector of patterns of volatile variation and
thus provides prima facie evidence that a signal is present. However, it is unlikely that animals will be used for actual diagnostic
purposes. Hence, it is crucial to devise chemometric approaches
that will accomplish this. Indeed, one might argue that behavioral
experiments could be dispensed with entirely and that all work

P. Millet et al. / Brain, Behavior, and Immunity 69 (2018) 312–320

with diagnostics in mind should employ chemical analysis
approaches much as it does in searches for other biochemical
and molecular biological biomarkers of disease. We disagree with
this approach and continue to believe that a combination of behavioral and chemical approaches will prove most fruitful in the long
run in identifying sensitive and specific signals of disease. As
advances are made in our understanding of how the mammalian
brain processes complex odor mixtures, we anticipate that novel
techniques of chemometric analysis will follow. Time will tell if
this speculation is correct.
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